Filing Flows

Filing Flows › Companies › Atara Biotherapeutics › Cash flow

Atara Biotherapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.3M in Q2 2026 · −$21.9M over twelve months

Operating cash flow−$3.3M
Free cash flow−$3.3M

Analysis

In Q2 2026, Atara Biotherapeutics generated −$3.3M of operating cash flow. That is $4.0M more than in Q2 2025 (−$7.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$21.9M; the largest uses were operating cash flow ($21.9M), other investing ($1.2M), other financing ($461K); besides operations, cash came from shares issued ($9.3M), asset & business sales ($599K); the cash balance fell by $13.7M.

Operating cash flow was −$3.3M against net income of −$4.8M. The largest differences: stock-based pay +$394K, receivables −$318K, other liabilities +$247K.

Free cash flow

Atara Biotherapeutics: free cash flow by quarterAtara Biotherapeutics: free cash flow by quarter−$4.0MQ3 2024−$24.6MQ4 2024−$28.1MQ1 2025−$7.3MQ2 2025−$9.8MQ3 2025−$5.7MQ4 2025−$3.1MQ1 2026−$3.3MQ2 2026
Operating cash flow less capital spending.
Atara Biotherapeutics: operating cash flow against capital spendingAtara Biotherapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$4.0M$0Q3 2024−$24.5M$90KQ4 2024−$28.1M$0Q1 2025−$7.3M$0Q2 2025−$9.8M$0Q3 2025−$5.7M$0Q4 2025−$3.1M$0Q1 2026−$3.3M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$3.3M, Capital spending $0.

Capital allocation, year by year

Atara Biotherapeutics: where the cash came from (up) and went (down), by fiscal yearAtara Biotherapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$221MFY2021: Net borrowing −$254KFY2021: Shares issued $105MFY2021: Capital spending −$10.6M$105MFY2021FY2022: Operating cash flow −$270MFY2022: Net borrowing −$518KFY2022: Shares issued $23.8MFY2022: Asset sales $94.8MFY2022: Capital spending −$4.2M$119MFY2022FY2023: Operating cash flow −$193MFY2023: Net borrowing −$947KFY2023: Shares issued $3.1MFY2023: Asset sales $25KFY2023: Capital spending −$1.2M$3.1MFY2023FY2024: Operating cash flow −$68.7MFY2024: Net borrowing −$892KFY2024: Shares issued $9.6MFY2024: Capital spending −$246K$9.6MFY2024FY2025: Operating cash flow −$50.9MFY2025: Net borrowing −$250KFY2025: Shares issued $1.5MFY2025: Asset sales $948K$2.5MFY2025
Over these 5 years operating cash flow totalled −$804M; the largest uses were operating cash flow ($804M) and capital spending ($16.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$9.9M
Debtnone
Net cash$9.9M
Cash runway5 months

Atara Biotherapeutics is burning cash: its operations consume cash, a free cash flow of −$21.9M a year at the current rate against $9.9M of cash and investments: a runway of about 5 months before any new financing.

Where the cash came from and went

Atara Biotherapeutics: sources (+) and uses (−) of cash, Q2 2026Atara Biotherapeutics: sources (+) and uses (−) of cash, Q2 2026Other investing−$6.6MCash drawn (+) / kept (−)$5.1MShares issued$4.8MOperating cash flow−$3.3M
Atara Biotherapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Atara Biotherapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$21.9MCash drawn (+) / kept (−)$13.7MShares issued$9.3MOther investing−$1.2MAsset & business sales$599KOther financing−$461K

From profit to cash

Atara Biotherapeutics: net income to operating cash flow, Q2 2026Atara Biotherapeutics: net income to operating cash flow, Q2 2026Net income−$4.8MDepreciation & amortization$14KStock-based pay$394KReceivables−$318KPayables$187KEmployee-related liabilities$70KDeferred revenue$91KPrepaid and other assets$125KOther liabilities$247KOperating cash flow−$3.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$3.3M——$4.8M$5.1M−$3.3M
Q1 2026−$3.1M——$3.0M$122K−$3.1M
Q4 2025−$5.7M——−$3K−$2.7M−$5.7M
Q3 2025−$9.8M——$1.5M$11.2M−$9.8M
Q2 2025−$7.3M———−$2.9M−$7.3M
Q1 2025−$28.1M—−$250K—$11.2M−$28.1M
Q4 2024−$24.5M−$90K−$235K$117K$21.4M−$24.6M
Q3 2024−$4.0M—−$197K—−$15.1M−$4.0M

Atara Biotherapeutics: income statement and cash flow

Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%. The chart follows the revenue to costs, profit and cash.

Atara Biotherapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.